Article
Phenotype-driven screening of semi-synthetic terpene analogs identifies TRX-41 as a lead compound active in chemotherapy-resistant breast cancer organoids.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Oct 2026
Mo Ariela, Dos Santos E Silva Gabriel, Dos Reis Dijovani Batista, Santana William Junior, De Almeida Luma Soares, Simões Lucas Damé, Magalhães Yuli T, Forti Fabio Luis, Dos Santos Ernande Xavier, Canteli Amanda R A, Saccarelli Carolina Rossi, Moysés Larissa Assad João, Yamashita Ligia Akemi, de Camargo Teixeira Patricia Akissue, Kobayashi Thiago Yoshio, de Siqueira Ferreira Vera Christina Camargo, Omura Vivian Larissa Nakamura, De Cássia Muller Valentine, Farias Jandrey Elisa H, Santos Giulia Luiza, Inoue Lilian Tiemi, Fernandes Bianca Ventura, Chammas Roger, de Barros Alfredo Carlos S D, Bevilacqua José Luiz B, Camargo Anamaria Aranha, Giannotti Daniela G, Saraiva Mauricio Frota, Costa Érico Tosoni
Abstract excerpt
Natural products remain an important source of anticancer agents, yet identifying pharmacological vulnerabilities in chemotherapy-refractory tumors remains a major challenge. Natural terpenes (NT) represent one of the most structurally diverse classes of bioactive compounds, but their native scaffolds often display limited potency and restricted translational potential. Here, we applied a phenotype-driven...
Read the complete abstract on PubMedTopics
- Humans
